Evidence map›Paper›PMID 41556350›Full record

ArticleCPT: pharmacometrics & systems pharmacology2026

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole.

Laura G Al-Amiry Santos, Sebastian Polak, Karen Rowland Yeo

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laura G Al-Amiry SantosCertara UK Limited, Sheffield, UK.ORCID https://orcid.org/0009-0002-8010-9278
Sebastian PolakCertara UK Limited, Sheffield, UK.ORCID https://orcid.org/0000-0001-8614-0642
Karen Rowland YeoCertara UK Limited, Sheffield, UK.ORCID https://orcid.org/0000-0002-7020-1970

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A high number of poorly soluble compounds are being developed; thus, understanding the factors that influence their absorption is critical. Intestinal bile salts, which facilitate micelle-mediated solubilization, are particularly important for drugs with low solubility and are reported to be highly variable. The aim of this study was to evaluate the effect of luminal bile salt concentrations on the absorption of poorly soluble compounds, using efavirenz, cinnarizine, and posaconazole as examples. Physiologically-based pharmacokinetic (PBPK) models were developed and validated using the Simcyp Simulator. Sensitivity analyzes were performed to assess the impact of bile salts and other gastrointestinal parameters on drug absorption. Simulations revealed that drug absorption in the fasted state was most sensitive to bile salt concentrations compared to other gastrointestinal parameters such as luminal pH, fluid volumes, and gastric emptying. The findings indicate that efavirenz, cinnarizine, and posaconazole exhibit high micelle-mediated solubility, with bile salts playing a critical role in their absorption, particularly in the fasted state. These results highlight the importance of considering bile salt concentrations in PBPK modeling of poorly soluble compounds.

Indexed as

BenzoxazinesBile Acids and SaltsCinnarizineIntestinal AbsorptionModels, BiologicalTriazolesAlkynesComputer SimulationCyclopropanesHumansSolubilityAlkynesBenzoxazinesBile Acids and SaltsCinnarizineCyclopropanesefavirenzposaconazoleTriazolesdrug absorptionintestinal bile saltsPBPK modelingpharmacokineticssensitivity analysis

Identifiers

PMID41556350
PMCPMC12823294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.